These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 22187803

  • 1. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
    Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H.
    J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 3. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 4. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 5. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 6. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 7. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 8. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M, Pinget M, Gin H, Thivolet C, Hanaire H, Robert JJ, Fontaine P.
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [Abstract] [Full Text] [Related]

  • 9. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 10. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 11. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 12. [The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
    Pan CY, Ji LN, Lu JM, Yang WY, Zhou ZG, Zou DJ, Ji QH, Han P, Liu J, Li Q, Su BL, Li YB, Gao ZN, Wang PH, Yin SN, Dong YH, Yang T, Sun K, Li H, Hong X, Lin J, Shi JM, Yang XJ, Fang H, Yan XD, SOLVE™ Chinese study group.
    Zhonghua Nei Ke Za Zhi; 2013 Jan; 52(1):11-5. PubMed ID: 23710808
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.
    J Med Econ; 2013 Jan; 16(4):468-78. PubMed ID: 23384160
    [Abstract] [Full Text] [Related]

  • 14. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
    Pan C, Han P, Ji L, Ji Q, Lu J, Lin J, Liu J, Su B, Shi J, Wang P.
    J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
    [Abstract] [Full Text] [Related]

  • 15. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M, Honka M.
    Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 17. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 18. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [Abstract] [Full Text] [Related]

  • 19. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL, SOLVE Study Group.
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [Abstract] [Full Text] [Related]

  • 20. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Kshanti IA, Pramono RB, Langi YA, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.